Cancer remains one of the major challenges of the 21st century. The increasing number of cases are not accompanied by adequate progress in therapy. The standard methods of treatment often do not lead to the expected effects. Therefore, it is extremely important to find new, more effective treatments. One of the most promising research directions is immunotherapy, including the use of specific types of microorganisms. This type of treatment is expected to stimulate the immune system for the selective elimination of cancer cells. It is possible to use microorganisms in many different ways, based on their specific properties, that is, toxin production, anaerobic lifestyle, or binding substances that can be delivered to a specific location (vectors).
The main priorities in cancer research are prevention, early detection, and the development of new therapies, including personalized therapies, which are intended to include the molecular biology of a particular tumor and the predisposition of the patient’s immune system. Among the known and practiced anticancer therapies, the use of microbes appears to be one of the most promising strategies. Although now somewhat forgotten, it has a large potential to play a significant role in the treatment of cancer. Thus, microbial-based cancer therapy aims to use tumor-specific infectious microbes to fulfill the unmet medical needs for patients with difficult-to-treat malignancies.
This special issue focuses on the interaction of microbe-tumor and discusses recent advances in the field that take advantage of the unique ability of microbes to invade human cells and induce immune responses in order to create therapeutic approaches that direct microbes to selectively target tumors.
The goal of this special issue is to recruit manuscripts describing the use of recombinant bacteria and viruses that express immunotherapeutic genes for cancer immunotherapy and immunoprevention.
In this special issue, we welcome original research, reviews, and brief reports.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Cancer remains one of the major challenges of the 21st century. The increasing number of cases are not accompanied by adequate progress in therapy. The standard methods of treatment often do not lead to the expected effects. Therefore, it is extremely important to find new, more effective treatments. One of the most promising research directions is immunotherapy, including the use of specific types of microorganisms. This type of treatment is expected to stimulate the immune system for the selective elimination of cancer cells. It is possible to use microorganisms in many different ways, based on their specific properties, that is, toxin production, anaerobic lifestyle, or binding substances that can be delivered to a specific location (vectors).
The main priorities in cancer research are prevention, early detection, and the development of new therapies, including personalized therapies, which are intended to include the molecular biology of a particular tumor and the predisposition of the patient’s immune system. Among the known and practiced anticancer therapies, the use of microbes appears to be one of the most promising strategies. Although now somewhat forgotten, it has a large potential to play a significant role in the treatment of cancer. Thus, microbial-based cancer therapy aims to use tumor-specific infectious microbes to fulfill the unmet medical needs for patients with difficult-to-treat malignancies.
This special issue focuses on the interaction of microbe-tumor and discusses recent advances in the field that take advantage of the unique ability of microbes to invade human cells and induce immune responses in order to create therapeutic approaches that direct microbes to selectively target tumors.
The goal of this special issue is to recruit manuscripts describing the use of recombinant bacteria and viruses that express immunotherapeutic genes for cancer immunotherapy and immunoprevention.
In this special issue, we welcome original research, reviews, and brief reports.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
